A Phase 2 interventional study of Anti-Beta Interferon (PF-06823859) in Dermatomyositis, sponsored by Pfizer. Completed at 25 sites in 4 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-02-06.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 94 studies in Dermatomyositis with a site in United States — 30 open to participants now, 33 under way, 6 of them phase 3. Dermatomyositis · United States.
Among the 94 studies in Dermatomyositis with a site in United States, this one is the 38th largest by enrollment of the 73 interventional ones that give a count, is one of 4 that started in 2021, is one of 31 in phase 2, and was the 58th registered.
184 studies on the registry are indexed under Dermatomyositis; 63 are open to participants now.
Browse Dermatomyositis studies →30 of the 94 studies in Dermatomyositis with a site in United States are open now. Recruiting first, the newest first:
National Institute of Environmental Health Sciences (NIEHS) · Sites in United States
Ages 18–62
Fate Therapeutics · Sites in United States
Ages 18–70
University of Miami · Sites in United States
Ages 18+
Cartesian Therapeutics · Sites in United States
Ages 12+
Restem, LLC. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 50 Dermatomyositis studies recruiting now, 24 (48%) set no upper age limit and 16 (32%) stop at 75 or younger; 15 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
94 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 42 · Phase 3 17 · Phase 4 2
First in 1990; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 35 across 130 interventional studies indexed under Dermatomyositis.
Median enrollment 25 across the 73 interventional studies, 540 across the 18 observational. Of the 55 that completed or were terminated, 26 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
40 of 94 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 4 studies filed under Dermatomyositis — fewer than ten, so there is no comparison to draw.
5 of the studies in Dermatomyositis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06284954argenxA Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis | 2026-11 |
| NCT06371417Chugai PharmaceuticalPhase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) | 2027-03-31 |
| NCT06298019Stanford UniversityStudy of KYV-101 Anti-CD19 CAR T Therapy in Adult Dermatomyositis | 2027-04 |
| NCT06916806AstraZenecaA Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis. | 2027-05-05 |
| NCT07486869University of MiamiEmapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study | 2027-07 |
Add all 5 to your calendar (.ics) → With an account.
Among the 94 studies in Dermatomyositis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this research study is to evaluate the long-term safety, and tolerability of PF-06823859 study drug in adult participants with Dermatomyositis (DM) from a qualifying study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
IV infusion
Drug: Anti-Beta Interferon (PF-06823859)
IV infusion
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
An Adverse Event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered treatment emergent relative to a given treatment if the event occurred for the first time during the effective duration of treatment and was not seen prior to the start of treatment, or the event was seen prior to the start of treatment but increased in severity during treatment. AEs included both serious adverse events (SAEs) and all non-SAEs.
Time frame: From Day 1 of dosing maximum up to Week 68
Number of Participants With Laboratory Abnormalities
Hematology laboratory parameters: hemoglobin (grams per deciliter \[g/dL\]); hematocrit (percentage \[%\]); lymphocytes (10\^3 per (/) millimeter\[mm\]\^3); lymphocytes/leukocytes (%); neutrophils (10\^3/mm\^3) less than (\<)0.8\*lower limit of normal (LLN), leukocytes (10\^3/mm\^3) \<0.6\*LLN, neutrophils (10\^3/mm\^3); basophils (10\^3/mm\^3); basophils/leukocytes (%); monocytes/leukocytes (%); activated partial thromboplastin time (seconds \[sec\]); prothrombin time (sec) more than (\>)1.2\*upper limit of normal (ULN). Clinical chemistry: potassium (milliequivalents per liter \[mEq/L\]); bicarbonate (mEq/L) \<0.9\*LLN, creatine kinase (units per liter \[U/L\]) \>2.0\*ULN, glucose (milligram per deciliter \[mg/dl\]); glucose-fasting (mg/dl) \>1.5\*ULN. Urinalysis: Urine glucose; ketones; urine protein; urine hemoglobin; nitrite; leukocyte esterase; hyaline casts (1/per leukocytosis promoting factor (more than or equal to \[\>=\] 1, urine erythrocytes (scalar); urine leukocytes (scalar) \>=20.
Time frame: From Day 1 of dosing maximum up to Week 68
Number of Participants According to Categorization of Changes in Vital Signs
Vital signs included the following parameters: sitting diastolic blood pressure (millimetres of mercury \[mmHg\]) change \>=20 mmHg increase; sitting systolic blood pressure (mmHg) change \>=30 mmHg increase, sitting diastolic blood pressure (mmHg) change \>=20 mmHg decrease and sitting systolic blood pressure (mmHg) change \>=30 mmHg decrease.
Time frame: From Day 1 of dosing maximum up to Week 68
Number of Participants According to Categorization of Electrocardiogram (ECG) Findings
ECG parameters evaluated were: PR interval value \>=300 milliseconds (msec); QRS duration value \>=200 msec; QT interval value \>=500 msec; corrected QT Interval using Fridericia's formula (QTCF) 450 less than or equal to (\<=) value \<480 msec, 480 \<=value\<500 msec and value\>=500 msec.
Time frame: From Day 1 of dosing maximum up to Week 68
Change From Baseline in Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) Activity Score at Week 52
CDASI is a validated DM-specific instrument designed to systematically quantify the extent of cutaneous disease. Disease involvement in 15 different anatomical locations was rated using three activity (erythema, scale, erosion/ulceration) and two damage (poikiloderma, calcinosis) measures. The presence and severity of Gottron's papules, periungual changes and alopecia were also captured. Total CDASI activity score was based on the physician's evaluation of three activities (erythema, scale, erosion/ulceration), presence and severity of Gottron's papules, periungual changes and alopecia. Total CDASI activity score ranged from 0 to 100, where higher scores indicated higher levels of disability.
Time frame: Baseline (before dose 1), Week 52
Change From Baseline in CDASI Activity Score at Weeks 12, 24, 36, and 48
CDASI is a validated DM-specific instrument designed to systematically quantify the extent of cutaneous disease. Disease involvement in 15 different anatomical locations was rated using three activity (erythema, scale, erosion/ulceration) and two damage (poikiloderma, calcinosis) measures. The presence and severity of Gottron's papules, periungual changes and alopecia were also captured. Total CDASI activity score was based on the physician's evaluation of three activities (erythema, scale, erosion/ulceration), presence and severity of Gottron's papules, periungual changes and alopecia. Total CDASI activity score ranged from 0 to 100, where higher scores indicated higher levels of disability.
Time frame: Baseline (before dose 1), Weeks 12, 24, 36 and 48
Absolute Values of CDASI Activity Score at Weeks 12, 24, 36, 48, and 52
CDASI is a validated DM-specific instrument designed to systematically quantify the extent of cutaneous disease. Disease involvement in 15 different anatomical locations was rated using three activity (erythema, scale, erosion/ulceration) and two damage (poikiloderma, calcinosis) measures. The presence and severity of Gottron's papules, periungual changes and alopecia were also captured. Total CDASI activity score was based on the physician's evaluation of three activities (erythema, scale, erosion/ulceration), presence and severity of Gottron's papules, periungual changes and alopecia. Total CDASI activity score ranged from 0 to 100, where higher scores indicated higher levels of disability.
Time frame: Weeks 12, 24, 36, 48 and 52
Change From Baseline in CDASI Damage Score at Weeks 12, 24, 36, 48, and 52
CDASI is a validated DM-specific instrument designed to systematically quantify the extent of cutaneous disease. Disease involvement in 15 different anatomical locations was rated using three activity (erythema, scale, erosion/ulceration) and two damage (poikiloderma, calcinosis) measures. The presence and severity of Gottron's papules, periungual changes and alopecia were also captured. Total CDASI damage score was based on the physician's evaluation of two damage (poikiloderma, calcinosis) measures, and presence and severity of Gottron's papules. Total CDASI damage score ranged from 0 to 32, where higher scores indicated higher level of skin damage.
Time frame: Baseline (before dose on Day 1), Weeks 12, 24, 36, 48 and 52
Absolute Values of CDASI Damage Score at Weeks 12, 24, 36, 48, and 52
CDASI is a validated DM-specific instrument designed to systematically quantify the extent of cutaneous disease. Disease involvement in 15 different anatomical locations was rated using three activity (erythema, scale, erosion/ulceration) and two damage (poikiloderma, calcinosis) measures. The presence and severity of Gottron's papules, periungual changes and alopecia were also captured. Total CDASI damage score was based on the physician's evaluation of two damage (poikiloderma, calcinosis) measures, and presence and severity of Gottron's papules. Total CDASI damage score ranged from 0 to 32, where higher scores indicated higher level of skin damage.
Time frame: Weeks 12, 24, 36, 48 and 52
Total Improvement Score (TIS) at Weeks 12, 24, 36, 48 and 52: Muscle Cohort
There are 6 core set measure that comprised of TIS: 1) Physician Global Assessment Score \[PhGA\] (from Myositis Disease Activity Assessment Tool \[MDAAT\], 0-100 mm or 0-10 centimeter (cm) on visual analogue scale \[VAS\], higher scores= worse health status); 2) Patient Global Assessment Score \[PtGA\] (0-100 mm or 0-10 cm on VAS, higher scores= worse status); 3) Manual Muscle Testing-8 (MMT-8) designated muscle groups (0-80, lower scores= higher level of disability); 4) Health Assessment Questionnaire Disability Index \[HAQ-DI\] (0-3, higher scores= worse status); 5) Global Extramuscular Disease Activity (from MDAAT, 0-10 cm on a VAS, higher scores= higher level of disability); 6) Participant's most elevated muscle enzymes. TIS was sum of all 6 improvement scores associated with the change in each core set measure. TIS ranged from 0 to 100; where TIS\>=20 shows minimal improvement, TIS \>=40 shows moderate improvement and TIS \>= 60 shows major improvement.
Time frame: Weeks 12, 24, 36, 48 and 52
Change From Baseline in Physician Global Assessment (PhGA) Score at Week 12, 24, 36, 48 and 52: Muscle Cohort
PhGA: Investigator was asked to evaluate the participant's overall disease activity on a VAS of 0 cm (very good) to 10 cm (very poor), higher scores indicated worse health status.
Time frame: Baseline (before dose on day 1), Weeks 12, 24, 36, 48 and 52
Change From Baseline in Patient Global Assessment (PtGA) Score at Weeks 12, 24, 36, 48 and 52: Muscle Cohort
PtGA was the assessment of the severity of disease by the participant/participant's guardian, using a VAS from 0 mm (no evidence of disease activity) to 100 mm (extremely active or severe disease activity). Higher score indicated worse status.
Time frame: Baseline (before dose on day 1), Weeks 12, 24, 36, 48 and 52
Change From Baseline in Manual Muscle Testing-8 Designated Muscle Groups (MMT-8) Score at Weeks 12, 24, 36, 48 and 52: Muscle Cohort
MMT-8 is a tool that assesses muscle strength using manual muscle testing. Eight designated muscles are tested unilaterally with a total potential summed score of 0-80. Lower scores indicated a higher level of disability.
Time frame: Baseline (before dose on day 1), Weeks 12, 24, 36, 48 and 52
Change From Baseline in Health Assessment Questionnaire and Disease Index (HAQ-DI) Score at Weeks 12, 24, 36, 48 and 52: Muscle Cohort
HAQ-DI consisted of eight sections (including dressing \& grooming, arising, eating, walking, hygiene, grip, reach, and activities). Each section had multiple questions that the participant used to rank their functionality and ranged from 0 to 3 where 0 = without any difficulty and 3 = unable to do. For each participant, the average ranking was calculated for each of the eight sections. HAQ-DI had a score range of 0 to 3, where higher score reflected worse status.
Time frame: Baseline (before dose on day 1), Weeks 12, 24, 36, 48 and 52
Change From Baseline in Creatine Kinase at Weeks 12, 24, 36, 48 and 52: Muscle Cohort
Creatine kinase is a muscle enzyme measured in units per liter (U/L).
Time frame: Baseline (before dose on day 1), Weeks 12, 24, 36, 48 and 52
Change From Baseline in Extramuscular Global Assessment From the Myositis Disease Activity Assessment Tool (MDAAT) Score at Weeks 12, 24, 36, 48 and 52: Muscle Cohort
MDAAT tool measures the degree of disease activity of extramuscular organ systems and muscle on a VAS of 0 to 10 cm, higher scores indicated higher level of disability.
Time frame: Baseline (before dose on day 1), Weeks 12, 24, 36, 48 and 52
Eligible participants with moderate to severe dermatomyositis (DM) who completed the treatment period of qualifying study C0251002 \[NCT03181893\] and had agreement from their study doctor to continue active treatment were enrolled in this study. A total of 24 participants (9 participants from the skin predominant cohort \[Amended stage 2\] and 15 participants from the muscle predominant cohort \[Stage 3\]) of the study C0251002 were enrolled in this open label, long-term extension (OLE) study.
| Milestone | PF-06823859 600mg: All Participants |
|---|---|
| Started | 24 |
| Safety analysis set | 24 |
| Skin analysis set | 9 |
| Muscle analysis set | 15 |
| Completed | 21 |
| Not completed | 3 |
| Withdrew: Other | 1 |
| Withdrew: Lack of efficacy | 1 |
| Withdrew: Withdrawal by subject | 1 |
| Milestone | PF-06823859 600mg: All Participants |
|---|---|
| Started | 22 |
| Completed | 21 |
| Not completed | 1 |
| Withdrew: Withdrawal by subject | 1 |
An Adverse Event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered treatment emergent relative to a given treatment if the event occurred for the first time during the effective duration of treatment and was not seen prior to the start of treatment, or the event was seen prior to the start of treatment but increased in severity during treatment. AEs included both serious adverse events (SAEs) and all non-SAEs.
| Participants | PF-06823859 600mg: Skin Cohort | PF-06823859 600mg: Muscle Cohort | PF-06823859 600mg: All Participants |
|---|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 7 | 13 | 20 |
Hematology laboratory parameters: hemoglobin (grams per deciliter \[g/dL\]); hematocrit (percentage \[%\]); lymphocytes (10\^3 per (/) millimeter\[mm\]\^3); lymphocytes/leukocytes (%); neutrophils (10\^3/mm\^3) less than (\<)0.8\*lower limit of normal (LLN), leukocytes (10\^3/mm\^3) \<0.6\*LLN, neutrophils (10\^3/mm\^3); basophils (10\^3/mm\^3); basophils/leukocytes (%); monocytes/leukocytes (%); activated partial thromboplastin time (seconds \[sec\]); prothrombin time (sec) more than (\>)1.2\*upper limit of normal (ULN). Clinical chemistry: potassium (milliequivalents per liter \[mEq/L\]); bicarbonate (mEq/L) \<0.9\*LLN, creatine kinase (units per liter \[U/L\]) \>2.0\*ULN, glucose (milligram per deciliter \[mg/dl\]); glucose-fasting (mg/dl) \>1.5\*ULN. Urinalysis: Urine glucose; ketones; urine protein; urine hemoglobin; nitrite; leukocyte esterase; hyaline casts (1/per leukocytosis promoting factor (more than or equal to \[\>=\] 1, urine erythrocytes (scalar); urine leukocytes (scalar) \>=20.
| Participants | PF-06823859 600mg: Skin Cohort | PF-06823859 600mg: Muscle Cohort | PF-06823859 600mg: All Participants |
|---|---|---|---|
| Number of Participants With Laboratory Abnormalities | 8 | 14 | 22 |
Vital signs included the following parameters: sitting diastolic blood pressure (millimetres of mercury \[mmHg\]) change \>=20 mmHg increase; sitting systolic blood pressure (mmHg) change \>=30 mmHg increase, sitting diastolic blood pressure (mmHg) change \>=20 mmHg decrease and sitting systolic blood pressure (mmHg) change \>=30 mmHg decrease.
| Participants | PF-06823859 600mg: Skin Cohort | PF-06823859 600mg: Muscle Cohort | PF-06823859 600mg: All Participants |
|---|---|---|---|
| Increase: sitting diastolic blood pressure (mmHg) | 4 | 4 | 8 |
| Increase: sitting systolic blood pressure (mmHg) | 4 | 2 | 6 |
| Decrease: sitting diastolic blood pressure (mmHg) | 1 | 4 | 5 |
| Decrease: sitting systolic blood pressure (mmHg) | 1 | 3 | 4 |
ECG parameters evaluated were: PR interval value \>=300 milliseconds (msec); QRS duration value \>=200 msec; QT interval value \>=500 msec; corrected QT Interval using Fridericia's formula (QTCF) 450 less than or equal to (\<=) value \<480 msec, 480 \<=value\<500 msec and value\>=500 msec.
| Participants | PF-06823859 600mg: Skin Cohort | PF-06823859 600mg: Muscle Cohort | PF-06823859 600mg: All Participants |
|---|---|---|---|
| PR interval: value >=300 msec | 0 | 0 | 0 |
| QRS duration: value >=200 msec | 0 | 0 | 0 |
| QT interval: >=500 msec | 0 | 0 | 0 |
| QTCF: 450<=value<480 msec | 2 | 1 | 3 |
| QTCF: 480<=value<500 msec | 0 | 0 | 0 |
| QTCF: value>=500 msec | 0 | 0 | 0 |
CDASI is a validated DM-specific instrument designed to systematically quantify the extent of cutaneous disease. Disease involvement in 15 different anatomical locations was rated using three activity (erythema, scale, erosion/ulceration) and two damage (poikiloderma, calcinosis) measures. The presence and severity of Gottron's papules, periungual changes and alopecia were also captured. Total CDASI activity score was based on the physician's evaluation of three activities (erythema, scale, erosion/ulceration), presence and severity of Gottron's papules, periungual changes and alopecia. Total CDASI activity score ranged from 0 to 100, where higher scores indicated higher levels of disability.
| Units on a scale | PF-06823859 600mg: Skin Cohort | PF-06823859 600mg: Muscle Cohort |
|---|---|---|
| Change From Baseline in Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) Activity Score at Week 52 | -4.67 (-7.41 to -1.92) | -2.51 (-3.40 to -1.62) |
CDASI is a validated DM-specific instrument designed to systematically quantify the extent of cutaneous disease. Disease involvement in 15 different anatomical locations was rated using three activity (erythema, scale, erosion/ulceration) and two damage (poikiloderma, calcinosis) measures. The presence and severity of Gottron's papules, periungual changes and alopecia were also captured. Total CDASI activity score was based on the physician's evaluation of three activities (erythema, scale, erosion/ulceration), presence and severity of Gottron's papules, periungual changes and alopecia. Total CDASI activity score ranged from 0 to 100, where higher scores indicated higher levels of disability.
| Units on a scale | PF-06823859 600mg: Skin Cohort | PF-06823859 600mg: Muscle Cohort |
|---|---|---|
| Change at Week 12 | -5.28 (-7.67 to -2.90) | -0.87 (-1.98 to 0.25) |
| Change at Week 24 | -4.11 (-6.47 to -1.75) | -0.67 (-2.09 to 0.75) |
| Change at Week 36 | -4.51 (-7.90 to -1.11) | -1.40 (-2.40 to -0.40) |
| Change at Week 48 | -4.56 (-7.27 to -1.84) | -1.70 (-2.70 to -0.70) |
CDASI is a validated DM-specific instrument designed to systematically quantify the extent of cutaneous disease. Disease involvement in 15 different anatomical locations was rated using three activity (erythema, scale, erosion/ulceration) and two damage (poikiloderma, calcinosis) measures. The presence and severity of Gottron's papules, periungual changes and alopecia were also captured. Total CDASI activity score was based on the physician's evaluation of three activities (erythema, scale, erosion/ulceration), presence and severity of Gottron's papules, periungual changes and alopecia. Total CDASI activity score ranged from 0 to 100, where higher scores indicated higher levels of disability.
| Units on a scale | PF-06823859 600mg: Skin Cohort | PF-06823859 600mg: Muscle Cohort |
|---|---|---|
| Week 12 | 4.4 ± 2.45 | 4.4 ± 3.44 |
| Week 24 | 5.0 ± 3.71 | 4.6 ± 3.81 |
| Week 36 | 5.5 ± 5.13 | 3.9 ± 3.27 |
| Week 48 | 4.6 ± 4.45 | 3.1 ± 3.03 |
| Week 52 | 4.4 ± 4.85 | 2.2 ± 2.52 |
CDASI is a validated DM-specific instrument designed to systematically quantify the extent of cutaneous disease. Disease involvement in 15 different anatomical locations was rated using three activity (erythema, scale, erosion/ulceration) and two damage (poikiloderma, calcinosis) measures. The presence and severity of Gottron's papules, periungual changes and alopecia were also captured. Total CDASI damage score was based on the physician's evaluation of two damage (poikiloderma, calcinosis) measures, and presence and severity of Gottron's papules. Total CDASI damage score ranged from 0 to 32, where higher scores indicated higher level of skin damage.
| Units on a scale | PF-06823859 600mg: Skin Cohort | PF-06823859 600mg: Muscle Cohort |
|---|---|---|
| Change at Week 12 | -2.4 ± 2.77 | -0.8 ± 1.15 |
| Change at Week 24 | -1.8 ± 2.33 | -0.5 ± 1.19 |
| Change at Week 36 | -2.3 ± 2.25 | -0.5 ± 1.06 |
| Change at Week 48 | -2.0 ± 2.00 | -0.9 ± 1.24 |
| Change at Week 52 | -2.1 ± 2.09 | -0.9 ± 1.08 |
CDASI is a validated DM-specific instrument designed to systematically quantify the extent of cutaneous disease. Disease involvement in 15 different anatomical locations was rated using three activity (erythema, scale, erosion/ulceration) and two damage (poikiloderma, calcinosis) measures. The presence and severity of Gottron's papules, periungual changes and alopecia were also captured. Total CDASI damage score was based on the physician's evaluation of two damage (poikiloderma, calcinosis) measures, and presence and severity of Gottron's papules. Total CDASI damage score ranged from 0 to 32, where higher scores indicated higher level of skin damage.
| Units on a scale | PF-06823859 600mg: Skin Cohort | PF-06823859 600mg: Muscle Cohort |
|---|---|---|
| Week 12 | 0.9 ± 1.25 | 1.6 ± 3.07 |
| Week 24 | 1.9 ± 2.26 | 1.9 ± 3.41 |
| Week 36 | 1.4 ± 2.33 | 1.9 ± 3.43 |
| Week 48 | 1.7 ± 2.12 | 1.3 ± 2.83 |
| Week 52 | 1.6 ± 1.59 | 1.3 ± 3.19 |
There are 6 core set measure that comprised of TIS: 1) Physician Global Assessment Score \[PhGA\] (from Myositis Disease Activity Assessment Tool \[MDAAT\], 0-100 mm or 0-10 centimeter (cm) on visual analogue scale \[VAS\], higher scores= worse health status); 2) Patient Global Assessment Score \[PtGA\] (0-100 mm or 0-10 cm on VAS, higher scores= worse status); 3) Manual Muscle Testing-8 (MMT-8) designated muscle groups (0-80, lower scores= higher level of disability); 4) Health Assessment Questionnaire Disability Index \[HAQ-DI\] (0-3, higher scores= worse status); 5) Global Extramuscular Disease Activity (from MDAAT, 0-10 cm on a VAS, higher scores= higher level of disability); 6) Participant's most elevated muscle enzymes. TIS was sum of all 6 improvement scores associated with the change in each core set measure. TIS ranged from 0 to 100; where TIS\>=20 shows minimal improvement, TIS \>=40 shows moderate improvement and TIS \>= 60 shows major improvement.
| Units on a scale | PF-06823859 600mg: Muscle Cohort |
|---|---|
| Week 12 | 15.03 (8.36 to 21.70) |
| Week 24 | 15.67 (8.96 to 22.37) |
| Week 36 | 18.17 (10.84 to 25.49) |
| Week 48 | 19.61 (10.58 to 28.63) |
| Week 52 | 23.66 (14.05 to 33.28) |
PhGA: Investigator was asked to evaluate the participant's overall disease activity on a VAS of 0 cm (very good) to 10 cm (very poor), higher scores indicated worse health status.
| centimeter | PF-06823859 600mg: Muscle Cohort |
|---|---|
| Change at Week 12 | 0.17 (-0.54 to 0.87) |
| Change at Week 24 | 0.29 (-0.39 to 0.98) |
| Change at Week 36 | -0.18 (-0.59 to 0.23) |
| Change at Week 48 | -0.48 (-0.85 to -0.10) |
| Change at Week 52 | -0.60 (-0.97 to -0.23) |
PtGA was the assessment of the severity of disease by the participant/participant's guardian, using a VAS from 0 mm (no evidence of disease activity) to 100 mm (extremely active or severe disease activity). Higher score indicated worse status.
| millimeter | PF-06823859 600mg: Muscle Cohort |
|---|---|
| Change at Week 12 | 3.70 (-6.55 to 13.95) |
| Change at Week 24 | -9.63 (-18.18 to -1.08) |
| Change at Week 36 | -9.10 (-16.47 to -1.73) |
| Change at Week 48 | -8.36 (-14.74 to -1.97) |
| Change at Week 52 | -6.28 (-16.79 to 4.22) |
MMT-8 is a tool that assesses muscle strength using manual muscle testing. Eight designated muscles are tested unilaterally with a total potential summed score of 0-80. Lower scores indicated a higher level of disability.
| Units on a scale | PF-06823859 600mg: Muscle Cohort |
|---|---|
| Change at Week 12 | -0.06 (-5.93 to 5.82) |
| Change at Week 24 | 1.85 (-3.11 to 6.81) |
| Change at Week 36 | 4.92 (0.61 to 9.22) |
| Change at Week 48 | 8.00 (5.69 to 10.30) |
| Change at Week 52 | 9.84 (7.38 to 12.31) |
HAQ-DI consisted of eight sections (including dressing \& grooming, arising, eating, walking, hygiene, grip, reach, and activities). Each section had multiple questions that the participant used to rank their functionality and ranged from 0 to 3 where 0 = without any difficulty and 3 = unable to do. For each participant, the average ranking was calculated for each of the eight sections. HAQ-DI had a score range of 0 to 3, where higher score reflected worse status.
| Units on a scale | PF-06823859 600mg: Muscle Cohort |
|---|---|
| Change at Week 12 | 0.00 (-0.13 to 0.13) |
| Change at Week 24 | -0.10 (-0.21 to 0.01) |
| Change at Week 36 | -0.07 (-0.23 to 0.08) |
| Change at Week 48 | -0.12 (-0.24 to 0.00) |
| Change at Week 52 | -0.18 (-0.32 to -0.04) |
Creatine kinase is a muscle enzyme measured in units per liter (U/L).
| Units per liter | PF-06823859 600mg: Muscle Cohort |
|---|---|
| Change at Week 12 | -98.93 (-163.76 to -34.11) |
| Change at Week 24 | -58.53 (-127.24 to 10.17) |
| Change at Week 36 | -97.62 (-150.82 to -44.42) |
| Change at Week 48 | -72.04 (-161.48 to 17.39) |
| Change at Week 52 | -94.04 (-147.13 to -40.95) |
MDAAT tool measures the degree of disease activity of extramuscular organ systems and muscle on a VAS of 0 to 10 cm, higher scores indicated higher level of disability.
| centimeter | PF-06823859 600mg: Muscle Cohort |
|---|---|
| Change at Week 12 | 0.05 (-0.40 to 0.50) |
| Change at Week 24 | 0.23 (-0.23 to 0.68) |
| Change at Week 36 | 0.01 (-0.51 to 0.53) |
| Change at Week 48 | -0.16 (-0.91 to 0.59) |
| Change at Week 52 | -0.56 (-1.07 to -0.06) |
Collected over From Day 1 of dosing maximum up to Week 68. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PF-06823859 600mg: Skin Cohort | 0/9 (0%) | 1/9 (11.1%) | 7/9 (77.8%) |
| PF-06823859 600mg: Muscle Cohort | 0/15 (0%) | 2/15 (13.3%) | 13/15 (86.7%) |
| PF-06823859 600mg: All Participants | 0/24 (0%) | 3/24 (12.5%) | 20/24 (83.3%) |
| Event | PF-06823859 600mg: Skin Cohort | PF-06823859 600mg: Muscle Cohort | PF-06823859 600mg: All Participants |
|---|---|---|---|
| Lower limb fractureInjury, poisoning and procedural complications | 1/9 | 0/15 | 1/24 |
| CholelithiasisHepatobiliary disorders | 0/9 | 1/15 | 1/24 |
| Diabetic ketoacidosisMetabolism and nutrition disorders | 0/9 | 1/15 | 1/24 |
| Event | PF-06823859 600mg: Skin Cohort | PF-06823859 600mg: Muscle Cohort | PF-06823859 600mg: All Participants |
|---|---|---|---|
| COVID-19Infections and infestations | 3/9 | 3/15 | 6/24 |
| Upper respiratory tract infectionInfections and infestations | 2/9 | 0/15 | 2/24 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/9 | 0/15 | 2/24 |
| Abdominal painGastrointestinal disorders | 0/9 | 2/15 | 2/24 |
| Urinary tract infectionInfections and infestations | 1/9 | 2/15 | 3/24 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/9 | 2/15 | 2/24 |
| HeadacheNervous system disorders | 0/9 | 2/15 | 2/24 |
| AnaemiaBlood and lymphatic system disorders | 1/9 | 1/15 | 2/24 |
| PalpitationsCardiac disorders | 1/9 | 0/15 | 1/24 |
| DiarrhoeaGastrointestinal disorders | 1/9 | 0/15 | 1/24 |
Safety analysis set included all participants enrolled who took at least 1 dose of study intervention. This included all such participants regardless of which stage the participant entered from. Baseline as planned was presented for all participants/safety analysis set, skin cohort/analysis set and muscle cohort/analysis set.
| Age, Continuous(Years) | PF-06823859 600mg: All Participants |
|---|---|
| All Participants | 49.79 ± 12.73 |
| Skin Cohort | 51.78 ± 10.32 |
| Muscle Cohort | 48.60 ± 14.19 |
| Sex: Female, Male(Participants) | PF-06823859 600mg: All Participants |
|---|---|
| All Participants — Female | 20 |
| All Participants — Male | 4 |
| Skin Cohort — Female | 9 |
| Skin Cohort — Male | 0 |
| Muscle Cohort — Female | 11 |
| Muscle Cohort — Male | 4 |
| Ethnicity (NIH/OMB)(Participants) | PF-06823859 600mg: All Participants |
|---|---|
| All Participants — Hispanic or Latino | 5 |
| All Participants — Not Hispanic or Latino | 19 |
| All Participants — Unknown or Not Reported | 0 |
| Skin Cohort — Hispanic or Latino | 1 |
| Skin Cohort — Not Hispanic or Latino | 8 |
| Skin Cohort — Unknown or Not Reported | 0 |
| Muscle Cohort — Hispanic or Latino | 4 |
| Muscle Cohort — Not Hispanic or Latino | 11 |
| Muscle Cohort — Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | PF-06823859 600mg: All Participants |
|---|---|
| All Participants — American Indian or Alaska Native | 0 |
| All Participants — Asian | 0 |
| All Participants — Native Hawaiian or Other Pacific Islander | 0 |
| All Participants — Black or African American | 0 |
| All Participants — White | 24 |
| All Participants — More than one race | 0 |
| All Participants — Unknown or Not Reported | 0 |
| Skin Cohort — American Indian or Alaska Native | 0 |
| Skin Cohort — Asian | 0 |
| Skin Cohort — Native Hawaiian or Other Pacific Islander | 0 |
| Skin Cohort — Black or African American | 0 |
| Skin Cohort — White | 9 |
| Skin Cohort — More than one race | 0 |
| Skin Cohort — Unknown or Not Reported | 0 |
| Muscle Cohort — American Indian or Alaska Native | 0 |
| Muscle Cohort — Asian | 0 |
| Muscle Cohort — Native Hawaiian or Other Pacific Islander | 0 |
| Muscle Cohort — Black or African American | 0 |
| Muscle Cohort — White | 15 |
| Muscle Cohort — More than one race | 0 |
| Muscle Cohort — Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Dec 2021 to primary completion in Nov 2023, 23 months.
Results were first posted in Feb 2025, 1 year 2 months after primary completion.
Of 19 phase 2 interventional studies under Dermatomyositis, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 52. This study's 23 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dazukibart